Mucosal Anti-CD3 Monoclonal Antibody Attenuates Collagen-Induced Arthritis That Is Associated with Induction of LAP+ Regulatory T Cells and Is Enhanced by Administration of an Emulsome-Based Th2-Skewing Adjuvant

摘要: Mucosal (nasal or oral) administration of anti-CD3 mAb is effective in ameliorating animal models autoimmunity (experimental autoimmune encephalomyelitis, diabetes, and lupus) by inducing LAP+ regulatory T cells. We tested this approach an arthritis model using type II collagen. found that nasal was more than oral attenuating the development arthritis. Nasal induced a cell secreted high levels IL-10 suppressed collagen-specific proliferation anti-collagen Ab production. However, neither nor attenuated disease when given to animals with ongoing arthritis, associated lack induction found, however, coadministration novel emulsome adjuvant, which enhances Th2 responses, resulted cells suppression both anti-CD3. Suppression mucosal less joint damage, decrease TNF-α IFN-γ mRNA expression joints, reduction Abs. These results demonstrate therapy may serve as therapeutic biologic effect enhanced emulsome-based adjuvant.